Switch Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 25 2024 - 7:00AM
Business Wire
Switch Therapeutics, a biotechnology company pioneering a new
way to use RNA science to treat disease utilizing its proprietary
CASi (Conditionally Activated siRNA) platform, today announced that
Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will
present and host investor meetings at the H.C. Wainwright 5th
Annual Neuro Perspectives Virtual Conference on Thursday, June 27,
2024.
A recording of the webcast will be available on the conference
day starting at 7:00 a.m. ET (4:00 a.m. PT) and will be available
here. The webcast recording will be available for replay for 90
days following the conclusion of the conference.
About Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company
pioneering a new type of medicine, integrating nucleic acid
nanotechnology and RNA interference (RNAi) science to build a
unique pipeline focused on central nervous system (CNS) diseases,
with high unmet need. The CASi (Conditionally Activated siRNA)
Platform, the company’s novel gene knockdown approach, is based on
technology developed by renowned researchers in the field of RNA
and drug development from Caltech, Harvard Medical School and City
of Hope. CASi combines advantageous properties of both single and
double-stranded RNAs in a single molecule, allowing for efficient
self-delivery and uptake, potency and duration of effect, cell
selective RNAi activity and broad applicability beyond the CNS.
Switch is based in South San Francisco, California. For more
information, connect with Switch on LinkedIn or visit
www.switchthera.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625564323/en/
Media Contact: Tressa Frankel, Health+Commerce
tressa@healthandcommerce.com
Investor Contact: Kevin Lui, Precision AQ
kevin.lui@precisionaq.com